Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Avidity Biosciences, Inc. (RNA) Amortization of Deferred Charges (2019 - 2020)

Avidity Biosciences' Amortization of Deferred Charges history spans 2 years, with the latest figure at $20000.0 for Q2 2020.

For Q2 2020, Amortization of Deferred Charges changed N/A year-over-year to $20000.0; the TTM value through Mar 2021 reached $20000.0, changed N/A, while the annual FY2020 figure was $29000.0, 59.15% down from the prior year.
Amortization of Deferred Charges reached $20000.0 in Q2 2020 per RNA's latest filing, up from $9000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $27000.0 in Q3 2019 to a low of $9000.0 in Q1 2020.